Analysis Of Income And Expense [Abstract]

Innate Pharma - Filing #5981200

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue from sale of goods	11,000 EUR	—	—	—	—	—	—	—	—	—	11,000 EUR	—	—	—	—	—	—	—
Revenue	20 121 EUR	—	—	—	—	—	—	—	—	—	61 641 EUR	—	—	—	—	—	—	—
Material income and expense [abstract]
Research and development expense	51 980 EUR	—	—	—	—	—	—	—	—	—	56 022 EUR	—	—	—	—	—	—	—
Finance income (cost)	2 104 EUR	—	—	—	—	—	—	—	—	—	5 099 EUR	—	—	—	—	—	—	—
Selling, general and administrative expense [abstract]
Selling, general and administrative expense	19 716 EUR	—	—	—	—	—	—	—	—	—	18 288 EUR	—	—	—	—	—	—	—
Operating expense	71 696 EUR	—	—	—	—	—	—	—	—	—	74 310 EUR	—	—	—	—	—	—	—
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	504,000 EUR	— EUR	— EUR	— EUR	— EUR	504,000 EUR	— EUR	— EUR	504,000 EUR	— EUR	276,000 EUR	718,000 EUR	— EUR	— EUR	— EUR	994,000 EUR	— EUR	718,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	49 939 EUR	49 471 EUR	— EUR	— EUR	— EUR	—	— EUR	— EUR	468,000 EUR	— EUR	6 900 EUR	—	7 570 EUR	— EUR	— EUR	994,000 EUR	— EUR	324,000 EUR